AMA announces CPT update for pediatric COVID-19 vaccine candidate
AMA announces CPT update for pediatric COVID-19 vaccine candidate

AMA announces CPT update for pediatric COVID-19 vaccine candidate

CHICAGO – The American Medical Association (AMA) today announced an editorial update to Current Procedural Terminology (CPT)®)the country’s leading medical terminology code set for describing healthcare procedures and services that includes new product and administration codes assigned to the Moderna COVID-19 vaccine for children from 6 months to 5 years.

The Preliminary CPT codes are effective for use provided that Modern’s pediatric COVID-19 vaccine candidate is assigned an Emergency Use Authorization by the US Food and Drug Administration (FDA). The AMA is now releasing the CPT code update to ensure that electronic systems across the U.S. healthcare system are prepared in advance for potential FDA approval.

“Approval of a vaccine for children aged 5 and under would be another important milestone in the fight against COVID-19,” said AMA President Gerald Harmon, MD. “Extending COVID-19 vaccination protection to approximately COVID-19 “infection, hospitalization and death, and give their parents incredible peace of mind. We strongly urge all parents to get their infants and toddlers vaccinated as soon as they are eligible for a COVID-19 vaccine.”

CPT codes clinically separate each coronavirus vaccine and dosing schedule to enable data-driven tracking, reporting, and analysis that support planning and allocation during the public health response to the pandemic. To date, 38 CPT codes have been created for reporting COVID-19 vaccines.

To help ensure accurate coding and reporting of COVID-19 vaccines and immunization services, AMA offers a resource for vaccine code finder to help identify the appropriate CPT code combination for the type and dose of COVID-19 vaccine given to each patient.

For quick reference, the new product code and administration codes have been assigned to the Moderna COVID-19 vaccine for children aged 6 months to 5 years:

Product code

91311 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease) [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 25 mcg / 0.25 ml dosage, for intramuscular use

Administration codes

0111A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease) [COVID-19]) vaccine, mRNA-LNP, tip protein, preservative-free, 25 mcg / 0.25 ml dose; first dose

0112A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease) [COVID-19]) vaccine, mRNA-LNP, tip protein, preservative-free, 25 mcg / 0.25 ml dose; second dose

Short, medium and long descriptors for all the new vaccine-specific CPT codes can be accessed at AMA websitealong with other recent changes to the CPT Code Set that have helped streamline public health response to the SARS-CoV-2 virus and COVID-19 disease.

Changes to the CPT Code Set are considered through an open editorial process managed by the CPT Editorial Panel, which collects broad inputs from the healthcare system and beyond to ensure that CPT content reflects the coding requirements for digital health, precision medicine, enhanced intelligence and other aspects of a modern healthcare. This rigorous editorial process keeps the CPT code set updated with modern medical science and technology so that it can fulfill its vital role as the trusted language of medicine today and the code of its future.

# # #

Questions about CPT coding and content should be addressed CPT network, the authoritative source of CPT coding responses. See also AMA’s online library for COVID-19 CPT coding and guidance.

Leave a Reply

Your email address will not be published.